Department of Ophthalmology and Visual Science, Catholic University of Korea, Seoul, Republic of Korea.
Ophthalmologica. 2011;226(3):119-26. doi: 10.1159/000329466. Epub 2011 Jul 13.
To evaluate the safety and efficacy of intravitreal ranibizumab with or without photodynamic therapy (PDT) in the treatment of polypoidal choroidal vasculopathy (PCV) in Korean patients.
A retrospective chart review of 22 patients (24 eyes) with PCV was conducted. Nine eyes were treated with intravitreal ranibizumab combined with a single session of PDT (group 1), and 15 eyes were treated only with ranibizumab (group 2). Such clinical evaluations as best-corrected Snellen visual acuity, central retinal thickness (CRT) by optical coherence tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICGA) were done at baseline, 1, 3, 6, 9 and 12 months after the first injections. Ranibizumab was reinjected on an as-needed basis guided by OCT, FA and ICGA, or at the doctor's discretion.
The mean follow-up duration was 22.5 months (range 12-37). The mean best-corrected visual acuity (logMAR) improved, and the mean CRT decreased throughout 12 months in both groups; no statistically significant difference between the groups was found (p = 0.327, p = 0.073, respectively). The number of ranibizumab injections was not significantly different either (p = 0.555).
Intravitreal ranibizumab with or without PDT for PCV in Korean patients resulted in visual and anatomical improvement over the 1-year follow-up period.
评估玻璃体内雷珠单抗联合或不联合光动力疗法（PDT）治疗韩国患者息肉样脉络膜血管病变（PCV）的安全性和疗效。
回顾性分析 22 例（24 只眼）PCV 患者的病历。9 只眼接受玻璃体内雷珠单抗联合单次 PDT 治疗（第 1 组），15 只眼仅接受雷珠单抗治疗（第 2 组）。在首次注射后 1、3、6、9 和 12 个月进行最佳矫正视力、光学相干断层扫描（OCT）中央视网膜厚度（CRT）、荧光素血管造影（FA）和吲哚青绿血管造影（ICGA）等临床评估。根据 OCT、FA 和 ICGA 的结果，按需进行雷珠单抗再注射，或由医生决定。
平均随访时间为 22.5 个月（范围 12-37 个月）。两组的平均最佳矫正视力（logMAR）均有所提高，平均 CRT 在 12 个月内均有所下降；两组间无统计学差异（p = 0.327，p = 0.073）。雷珠单抗注射次数也无显著差异（p = 0.555）。
玻璃体内雷珠单抗联合或不联合 PDT 治疗韩国患者的 PCV，在 1 年的随访期内可改善视力和解剖结构。
